Healthtech funding in H2 2015
European Healthtech startup funding raised during H2 2015.
In H2 2015, 136 European Healthtech companies closed 141 funding rounds and raised €1.3B in equity funding (excluding debt and grants), up 135.6% versus H2 2014. Debt rounds added €103M. Switzerland led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.3B
+135.6% vs H2 2014 · excl. debt & grants · +€103M debt
Funding rounds
141
+120.3% vs H2 2014
Companies
136
Top country
Switzerland
Rank among sectors
#2
12.8% of sector funding
Debt financing
€103M
7.4% of total
Top-10 round share
45.9%
of disclosed capital
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H2 2015 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jul | €119M | 21 |
| Aug | €207M | 11 |
| Sep | €405M | 29 |
| Oct | €184M | 26 |
| Nov | €378M | 31 |
| Dec | €102M | 23 |
Top countries
by € raisedHealthtech — top countries by capital, H2 2015 — interactive chart.
Data table
| Healthtech — top countries by capital, H2 2015 | |
|---|---|
| Switzerland | €307M |
| UK | €289M |
| Israel | €146M |
| France | €131M |
| Germany | €116M |
| Netherlands | €107M |
| Spain | €71M |
| Denmark | €69M |
Stage mix
by € raisedHealthtech — stage mix, H2 2015 — interactive chart.
Data table
| Healthtech — stage mix, H2 2015 | |
|---|---|
| Series C | €367M |
| Series A | €252M |
| Growth/Late | €228M |
| Series B | €205M |
| Series D+ | €124M |
| Debt | €103M |
| Early VC | €58M |
| Seed | €41M |
| Grant | €17M |
| Other | €1.0M |
Exits & M&A
6 Acquisition6 exits · €526M disclosed.
| Biotie Therapies | Acquisition | Sep 2015 | €330M |
| WiThings | Acquisition | Dec 2015 | €170M |
| ClipFort | Acquisition | Dec 2015 | €26M |
Top deals
largest disclosed rounds in H2 2015| Company | Stage | Date | Amount |
|---|---|---|---|
| CureVac | Series D+ | Nov 2015 | €100M |
| CeQur | Series C | Sep 2015 | €89M |
| Benevolent | Growth/Late | Aug 2015 | €80M |
| Merus | Series C | Aug 2015 | €73M |
| ADC Therapeutics | Growth/Late | Sep 2015 | €71M |
| Symphogen | Debt | Oct 2015 | €68M |
| ObsEva | Series B | Nov 2015 | €54M |
| Sanifit | Series C | Sep 2015 | €37M |
| DNAe LTD | Debt | Nov 2015 | €35M |
| Bima | Series C | Jul 2015 | €34M |
| GenSight Biologics | Series B | Jul 2015 | €32M |
| NightstaRx | Series B | Nov 2015 | €32M |
| Biom'Up | Series C | Sep 2015 | €31M |
| Therachon | Series A | Sep 2015 | €31M |
| PREP Biopharm | Series A | Nov 2015 | €29M |
Top investors
most active in H2 2015, by deal count- High-Tech Gründerfonds (HTGF)7 deals
- Caixa Capital Risc3 deals
- Life Sciences Partners3 deals
- New Enterprise Associates3 deals
- Sofinnova Partners3 deals
- VI Partners3 deals
- Abingworth LLP2 deals
- Edmond de Rothschild Venture Capital2 deals
- Forbion2 deals
- GIMV2 deals